ZVSA — ZyVersa Therapeutics, Inc.
$0.00
+$0.00 (+0.00%)
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead.
Market Cap
$8095.00
Forward P/E
-0.0x
52-Week Range
N/A
ZVSA Price History
Revenue vs. Net Income
$0
Revenue · FY2023
Annual. Net margin is shown under each year.
Free Cash Flow
-$8.7M
FCF · FY2023
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-121.0%
ROCE · FY2023
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.0x
Assets ÷ liabilities · FY2023
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
97.5K
Diluted shares · FY2023
Only one year of share data is available, so no change can be shown yet.
